KEROS THERAPEUTICS INC's ticker is KROS and the CUSIP is 492327101. A total of 129 filers reported holding KEROS THERAPEUTICS INC in Q1 2023. The put-call ratio across all filers is 0.00 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,855,065 | -34.3% | 58,189 | -17.2% | 0.01% | -31.2% |
| Q2 2023 | $2,822,886 | +4.9% | 70,256 | +11.5% | 0.02% | -11.1% |
| Q1 2023 | $2,691,424 | -14.8% | 63,031 | -4.2% | 0.02% | -30.8% |
| Q4 2022 | $3,160,484 | +46.6% | 65,816 | +14.9% | 0.03% | +13.0% |
| Q3 2022 | $2,156,000 | +108.9% | 57,297 | +53.4% | 0.02% | +155.6% |
| Q2 2022 | $1,032,000 | -44.6% | 37,361 | +9.0% | 0.01% | -18.2% |
| Q1 2022 | $1,864,000 | -13.4% | 34,269 | -6.9% | 0.01% | 0.0% |
| Q4 2021 | $2,153,000 | +123.6% | 36,805 | +51.2% | 0.01% | +57.1% |
| Q3 2021 | $963,000 | -10.5% | 24,346 | -3.9% | 0.01% | 0.0% |
| Q2 2021 | $1,076,000 | -48.6% | 25,346 | -25.5% | 0.01% | -50.0% |
| Q1 2021 | $2,095,000 | +865.4% | 34,031 | +1004.9% | 0.01% | +600.0% |
| Q4 2020 | $217,000 | – | 3,080 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Foresite Capital Management IV, LLC | 1,412,705 | $99,652,000 | 10.82% |
| CHI Advisors LLC | 433,852 | $30,604,000 | 8.62% |
| VR Adviser, LLC | 672,306 | $47,424,000 | 6.97% |
| Consonance Capital Management LP | 557,095 | $39,297,000 | 3.67% |
| Logos Global Management LP | 450,000 | $31,743,000 | 2.72% |
| RA Capital Management | 1,875,000 | $132,263,000 | 1.85% |
| Nantahala Capital Management | 534,514 | $37,705,000 | 1.17% |
| Orbimed Advisors | 1,679,417 | $118,466,000 | 1.04% |
| Eventide Asset Management | 346,000 | $24,407,000 | 0.37% |
| Atom Investors LP | 49,981 | $3,526,000 | 0.36% |